Last reviewed · How we verify
IMP oral tablet
At a glance
| Generic name | IMP oral tablet |
|---|---|
| Also known as | Farexiga, gliflozin class, SGLT2 inhibitor, DUOFAG® |
| Sponsor | University of Leicester |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia (PHASE3)
- Testing APPA-1 in Healthy Subjects and Osteoarthritis Patients (PHASE1)
- Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome (PHASE2)
- Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward (PHASE3)
- Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. (PHASE3)
- Treatment of Bile Acid Diarrhoea With Atorvastatin (PHASE4)
- Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMP oral tablet CI brief — competitive landscape report
- IMP oral tablet updates RSS · CI watch RSS
- University of Leicester portfolio CI